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Population Landscape of Familial 
Cancer
C. Frank1, M. Fallah1, J. Sundquist2,3, A. Hemminki4 & K. Hemminki1,2
Public perception and anxiety of familial cancer have increased demands for clinical counseling, 
which may be well equipped for gene testing but less prepared for counseling of the large domain 
of familial cancer with unknown genetic background. The aim of the present study was to highlight 
the full scope of familial cancer and the variable levels of risk that need to be considered. Data 
on the 25 most common cancers were obtained from the Swedish Family Cancer Database and a 
Poisson regression model was applied to estimate relative risks (RR) distinguishing between family 
histories of single or multiple affected first-degree relatives and their diagnostic ages. For all cancers, 
individual risks were significantly increased if a parent or a sibling had a concordant cancer. While the 
RRs were around 2.00 for most cancers, risks were up to 10-fold increased for some cancers. Familial 
risks were even higher when multiple relatives were affected. Although familial risks were highest 
at ages below 60 years, most familial cases were diagnosed at older ages. The results emphasized 
the value of a detailed family history as a readily available tool for individualized counseling and its 
preventive potential for a large domain of non-syndromatic familial cancers.
Hereditary cancer has become an important issue in oncology clinics because of the success in imple-
menting genetic testing and/or screening methods for cancer syndromes. Most importantly, this infor-
mation has been useful in preventing new tumors and cancer deaths1,2. However, hereditary cancer 
syndromes with identified high-risk genes account only for a small proportion of familial cancers while 
familial aggregation has been suspected for practically all cancers many of which lack a fully dissected 
genetic background3. Public awareness of familial cancer has increased and the demand for counseling 
has been a challenge to the oncology community, firstly, on how to obtain and judge the family history 
of various cancers and, secondly, how to estimate the risk and propose management. In the general 
public the topic of familial cancer risk is characterized by apprehensiveness which may explain why 
poorly understood familial predisposition is overlooked or ambiguously communicated in the recom-
mendations of many professional organizations. The American Cancer Society considers a family history 
an indication for screening or surveillance only for cancers of the breast, prostate, colorectum, endome-
trium, and ovary but the focus is on mutation testing4. Similarly, the recent American Society of Clinical 
Oncology expert statement was strictly limited to cancer syndromes with known gene defects and the 
much larger domain of familial cancer with poorly defined genetics was not even mentioned5. Such a 
demarcation leaves 90% of familial cancers unattended, including prostate, lung and bladder cancers, 
and non-Hodgkin lymphoma for which gene testing may not be available6. With the recent emphasis 
on gene testing and the visions offered by next generation sequencing7, there is a danger that the valu-
able and readily available anamnestic information on family history remains unused, as if the concept 
of ‘individualized medicine’ would be restricted to the genetic make-up. A negative gene test does not 
overrule familial risk when no deleterious mutations have been found in the family. Therefore, there is 
no substitute for medical caregivers taking meticulous family histories. While generally there is little well 
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documented information of this issue, the available studies suggest that less than half of medical charts in 
the USA had any family history; even if recorded, the data were superficial, e.g., only dichotomous (yes 
or no) and lacking diagnostic ages8,9. In Europe, the situation is probably no better and in continental 
Europe counseling tends to be limited to gene testing. A contributing problem is that empirical data on 
familial risks have been limited; i.e., physicians have not been aware of the relevance of familial cancer 
risk for the patient being attended to, and thus obtaining the anamnesis has not been of sufficiently high 
priority to be included in medical records10.
In the present article we aimed to describe a nationwide landscape of familial cancer by defining the 
risk by the number and diagnostic age of affected family members, each factors that need to be considered 
in clinical genetic risk assessment. The analyses are based on the latest version of Swedish Family-Cancer 
Database (FCD 2010) which is a unique source for family studies comprising almost 15 million people 
with clinical cancer data and other detailed personal information from 1958 through 2010.
Methods
Data source and patients. The FCD was used to estimate familial cancer risks for the 25 most com-
mon cancer sites. The database comprises information from the Multigeneration Register, censuses and 
death notifications provided by Statistics Sweden, and information from the Swedish Cancer Registry. 
In its latest update from 2010 the database included 14.7 million individuals, where all people born in 
Sweden from 1932 onwards (the offspring generation) were registered with linkage to their biological 
parents (the parental generation).
More than 1.7 million medically verified cancer cases were recorded in the Cancer Registry from 1958 
to 2010. The 7th revision of the International Classification of Diseases (ICD-7) was used to identify the 
cancer type. Death information is assumed to be complete from 1961 onwards. In order to investigate 
cancer risks for offspring of affected parents as well as risk shared by siblings, all individuals with iden-
tified parents and non-missing information on birthday and sex were selected for the analysis, totaling 
in 8,148,737 index individuals. Among them 343,494 were diagnosed with one of the cancer sites under 
study.
Relative risk estimation. Familial risk was assessed for the offspring generation by estimating rela-
tive risks (RRs) in terms of incidence rate ratios using a Poisson regression model11. Hereby, incidence 
rates for people with a concordant cancer in a first-degree relative (FDR, positive family history) were 
compared to the corresponding rates for those individuals who had no concordant cancer among their 
FDRs (negative family history). Cases and person-years were counted first according to family history 
and stratified for sex, age group, calendar period, residential area, and socioeconomic status to account 
for potential confounders. These variables were used as covariates for the model building whereby cases 
were assumed to follow a Poisson distribution and person-years were included as offset12. The ratio of 
the fitted mean given a positive family history divided by the corresponding estimate for negative family 
history yielded the RR. Wald estimates were available to test for the significance of family history as a 
risk factor and to provide confidence intervals (CIs) for the RR. These were scaled using the Pearson 
chi-square estimate to account for potential dispersion13. Familial risk was considered to be significantly 
increased or decreased, respectively, if 1.00 was not included in the RR’s 95% CI which is equivalent with 
testing the significance of the regression coefficient for family history at the 5% confidence level.
Different levels of family history. In particular, independent groups for certain familial relation-
ships were considered in different settings in order to examine the differences in the familial risk shared 
by parents and siblings, the dependence on diagnostic age, and the risk shared by multiple affected rel-
atives. Risks for parental probands were calculated twice: First, with no limit on the parental diagnosis 
age and second, regarding only parental cancers if they were diagnosed until the age of 78 years. This 
cut-off was used for comparison reasons since it equaled with the maximum age for siblings in the FCD.
The dependence of familial risk on diagnostic age was investigated considering FDRs in general. We 
distinguished between cancer diagnosis before and after the 60th birthday for both index persons and 
their relatives. The corresponding diagnostic age specific RRs were tested for equality by a likelihood 
ratio test. Familial risks were also analyzed to check for differences when both parents, one parent and 
one sibling, or no parent but multiple siblings were affected. This analysis was limited to a subgroup of 
most common cancer sites due to sample size constraints.
Follow-up. The follow-up period started from the beginning of 1961, the birth year, or the immi-
gration year, whichever came latest. The follow-up was terminated when a person was diagnosed with 
cancer, emigrated or died, or at the end of 2010, whichever came first. The register-based definition of 
period at risk was used for person-year calculations whereby a person was considered to be at familial 
risk irrespective of when family members were diagnosed with cancer14.
Results
Risk estimates for siblings and offspring of affected patients. Familial risks were analyzed for 
25 different cancer sites for which at least 10 affected parent-offspring and sibling pairs were detected. 
All cancer types under study showed significantly increased risks at 5% confidence level for offspring 
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when their parents or siblings were affected, as shown in Table 1. Parents were used as probands with 
and without the age limit of 78 years (i.e., offspring maximal age), and for most cancers the RRs were 
only slightly higher if the parental age was limited. While the RRs for offspring of affected parents ranged 
between 1.5 and 2.5 for the majority of cancers, those for testicular cancer (3.90 and 3.96 with age limit, 
respectively), small intestine cancer (4.81–5.34), and cancer of the thyroid gland (5.13–5.61) were mark-
edly higher. RRs for siblings were considerably increased not only for the above sites (testicular cancer 
6.94, small intestine cancer 10.11, thyroid gland 5.43), but also for Hodgkin lymphoma (9.60). Sibling 
risks were higher than risks in offspring of affected parents (irrespective of parental age) for all cancer 
sites, except for endometrial cancer and cancers of the thyroid and other endocrine glands. Nonetheless, 
significance differences at the 5% level were only detected for stomach, colorectal, lung, prostate and 
testicular cancers, and Hodgkin lymphoma.
Early and late onset of familial cancers. Analyzing the data for familial risk for cancers diagnosed 
at early and late ages (Table 2), the results revealed increased familial risks for almost all cancers regard-
less of whether individual or relative diagnostic age was below or above 60 years. Even for familial risks 
which did not appear significantly increased (p-value ≥ 0.05), the RRs were greater than 1.00, except for 
elderly individuals with cervical cancer. The risk was highest for almost all cancers if index individuals 
and their relatives were affected at an early age. For some cancers the RRs seemed to decline in the order: 
young index persons/young relatives, old index persons/young relatives, young index persons/old rela-
tives, and both old index persons and relatives. Taking an example for prostate cancer, the RR declined 
in order 7.21, 3.51, 2.79, and 2.13. However, the respective familial cases increased in order 673, 916, 
Cancer site
Patients with 
negative fami-
ly history
1 parent affected
1 parent (age limited) 
affected1 1 sibling affected p-value for differ-
ence between RRsib 
and RRPar2N3 RR4 95% CI5 N RR 95% CI N RR 95% CI
Upper aerodigestive tract 7236 136 1.51 (1.13–2.02) 113 1.57 (1.14–2.15) 56 1.73 (1.10–2.72) 0.72
Esophagus 2248 26 2.45 (1.55–3.90) 18 2.33 (1.34–4.05) 12 3.36 (1.70–6.62) 0.41
Stomach 4411 222 1.72 (1.47–2.02) 172 1.78 (1.49–2.13) 46 2.97 (2.11–4.18) 0.0090
Small intestine 1489 17 4.81 (2.99–7.75) 14 5.34 (3.16–9.01) 14 10.11 (5.98–17.09) 0.09
Colorectum 25187 2945 1.72 (1.64–1.80) 2100 1.80 (1.71–1.90) 905 2.00 (1.84–2.17) 0.0294
Liver 4625 130 1.61 (1.29–1.99) 101 1.78 (1.39–2.27) 30 2.07 (1.32–3.23) 0.56
Pancreas 5152 178 1.96 (1.66–2.33) 140 2.09 (1.73–2.54) 54 2.73 (2.01–3.71) 0.15
Lung 18111 1346 1.86 (1.74–1.99) 1108 1.92 (1.78–2.07) 712 2.50 (2.28–2.74) <.0001
Breast 56566 6102 1.73 (1.67–1.80) 4989 1.78 (1.70–1.85) 3493 1.84 (1.75–1.94) 0.24
Cervix 8074 128 1.57 (1.28–1.93) 122 1.59 (1.29–1.96) 54 2.03 (1.48–2.78) 0.21
Endometrium 9298 301 2.21 (1.88–2.61) 257 2.37 (1.98–2.83) 128 2.13 (1.66–2.73) 0.49
Ovary 8633 261 2.52 (2.20–2.88) 241 2.67 (2.32–3.07) 122 2.97 (2.44–3.61) 0.38
Prostate 37805 6622 2.10 (2.03–2.18) 4469 2.33 (2.24–2.43) 3390 2.59 (2.48–2.72) 0.0005
Testis 6652 32 3.90 (2.63–5.79) 32 3.96 (2.67–5.86) 82 6.94 (5.42–8.89) 0.0173
Kidney 7739 201 1.58 (1.34–1.87) 175 1.68 (1.40–2.01) 75 2.09 (1.59–2.75) 0.18
Urinary bladder 10944 513 1.76 (1.56–1.98) 370 1.84 (1.61–2.12) 172 1.90 (1.55–2.32) 0.81
Melanoma 22807 763 2.43 (2.23–2.66) 643 2.55 (2.32–2.81) 584 2.74 (2.48–3.03) 0.31
Skin, squamous cell 8369 426 2.07 (1.86–2.29) 189 2.16 (1.85–2.52) 104 2.25 (1.83–2.77) 0.75
Nervous system 19099 371 1.54 (1.35–1.75) 349 1.58 (1.38–1.80) 215 1.71 (1.44–2.03) 0.45
Thyroid gland 4791 90 5.13 (3.91–6.74) 87 5.61 (4.25–7.40) 48 5.43 (3.74–7.87) 0.86
Endocrine glands 7810 130 2.05 (1.61–2.62) 110 1.99 (1.53–2.59) 60 1.98 (1.38–2.83) 0.98
Non–Hodgkin lymphoma 11895 276 1.61 (1.41–1.84) 203 1.65 (1.41–1.93) 124 1.69 (1.38–2.06) 0.85
Hodgkin lymphoma 3931 19 2.57 (1.65–3.98) 18 2.59 (1.65–4.07) 40 9.60 (7.08–13.00) <.0001
Myeloma 3296 61 2.12 (1.64–2.74) 40 1.96 (1.43–2.68) 22 2.73 (1.79–4.18) 0.21
Leukemia 12149 277 1.86 (1.62–2.14) 216 1.88 (1.61–2.20) 105 2.17 (1.73–2.71) 0.31
Table 1.  Familial cancer risks conferred by affected parents and siblings. 1Individuals were only 
considered to have a positive family history if the parental cancer was diagnosed at age ≤ 78 years. 2Risk 
estimates for limited parental age were considered for comparison. 3N = Number of cases with a concordant 
cancer in the family. 4RR = Relative risk. 5CI = Confidence interval.
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2727, and 7300. A trend test cannot be applied for these kinds of data but we tested the equality for RRs 
in the four independent age groups by a likelihood ratio test. In fact, RRs differed significantly from each 
other among age groups for the majority of cancer types.
It is noteworthy that among 23 cancer types with cases in the highest age category 19 showed a sig-
nificant increase. Among the four remaining cancer types the sample size for cervical and thyroid cancer 
was small and the RR for kidney cancer was almost significant (RR = 1.29 with corresponding 95% CI 
0.98–1.71). In agreement with prostate cancer, the other most common cancers, including colorectal, 
lung, bladder, and skin cancers showed the largest number of affected individuals in the highest age 
group and each with a significant familial risk. The exception for case numbers was breast cancer but 
the familial risk remained significant in the highest age group.
Familial cancer risks in multiplex families. Familial cancer risks when two or more FDRs were 
affected (i.e., multiplex families) with a concordant cancer and corresponding test statistics for significant 
differences among RRs were presented in Table  3. RRs for breast cancer (9.49) and melanoma (6.00) 
were strikingly increased when both parents were affected and the estimates differed significantly from 
those calculated for one affected parent in Table 1. If one parent and one sibling were affected, risks for 
cancers of the prostate (4.59) and the nervous system (9.47) and of melanoma (8.20) were two to five 
times higher compared to RRs for one affected FDR (Table 1). For all but lung and bladder cancers, the 
risks for individuals with an affected parent and a sibling were significantly higher than the risks for cases 
with one affected parent or sibling (all p-values < 0.0001). The risk estimates did not differ significantly 
between patients with one affected parent and sibling and patients with two affected siblings. The risk 
Cancer site
FDRs1 diagnosed at age < 60 years FDRs diagnosed at age ≥ 60 years
p-value for 
differences in 
RRs among all 
groups2
Index individuals at age < 60 
years
Index individuals at age ≥ 60 
years
Index individuals at 
age < 60 years
Index individuals at 
age ≥ 60 years
N3 RR4 95% CI5 N RR 95% CI N RR 95% CI N RR 95% CI
Upper aerodigestive tract 38 1.65 (0.92–2.99) 32 2.74 (1.44–5.22) 79 1.55 (1.03–2.34) 51 1.36 (0.81–2.27) 0.44
Esophagus 4 3.70 (1.02–13.50) 6 5.55 (1.93–16.00) 10 1.98 (0.87–4.49) 17 2.45 (1.30–4.59) 0.51
Stomach 39 2.70 (1.91–3.82) 33 3.14 (2.16–4.58) 94 1.72 (1.37–2.15) 107 1.69 (1.36–2.09) 0.0084
Small intestine 6 7.89 (3.54–17.60) 5 12.08 (5.02–29.10) 12 5.81 (3.29–10.30) 10 5.97 (3.20–11.10) 0.57
Colorectum 529 3.14 (2.82–3.49) 286 2.00 (1.74–2.31) 1563 1.80 (1.69–1.92) 1780 1.64 (1.54–1.74) < .0001
Liver 16 2.19 (1.20–4.00) 10 1.75 (0.82–3.73) 56 1.55 (1.12–2.14) 78 1.67 (1.27–2.21) 0.81
Pancreas 39 4.47 (3.14–6.37) 18 2.14 (1.28–3.60) 81 2.15 (1.68–2.76) 102 1.82 (1.46–2.28) 0.0016
Lung 274 2.77 (2.39–3.22) 229 2.31 (1.96–2.71) 707 1.95 (1.78–2.15) 937 1.96 (1.81–2.13) 0.0003
Breast 3854 2.15 (2.05–2.26) 1118 1.79 (1.64–1.96) 3730 1.67 (1.59–1.75) 1659 1.59 (1.48–1.71) < .0001
Cervix 134 1.85 (1.50–2.27) 4 0.72 (0.22–2.37) 39 1.48 (1.01–2.16) 3 0.88 (0.22–3.48) 0.18
Endometrium 149 4.31 (3.43–5.42) 56 1.89 (1.31–2.73) 120 1.70 (1.32–2.19) 127 1.97 (1.54–2.52) < .0001
Ovary 197 4.23 (3.65–4.90) 39 2.53 (1.82–3.52) 116 2.03 (1.68–2.45) 43 1.64 (1.20–2.24) < .0001
Prostate 673 7.21 (6.56–7.93) 916 3.51 (3.24–3.80) 2727 2.79 (2.64–2.94) 7300 2.13 (2.06–2.19) < .0001
Testis 118 6.25 (5.12–7.63) 1 4 0
Kidney 80 3.05 (2.33–3.98) 36 2.22 (1.49–3.31) 98 1.53 (1.20–1.95) 74 1.29 (0.98–1.71) < .0001
Urinary bladder 75 2.19 (1.63–2.94) 60 1.83 (1.32–2.55) 250 1.67 (1.42–1.97) 327 1.90 (1.64–2.20) 0.41
Melanoma 652 3.13 (2.84–3.44) 117 2.64 (2.11–3.31) 477 2.19 (1.96–2.45) 185 2.71 (2.26–3.25) < .0001
Skin, squamous cell 29 2.20 (1.47–3.31) 25 1.88 (1.21–2.90) 201 2.02 (1.73–2.37) 294 2.24 (1.97–2.56) 0.7
Nervous system 326 1.97 (1.68–2.32) 42 1.47 (0.94–2.30) 167 1.27 (1.01–1.59) 78 1.79 (1.29–2.49) 0.0121
Thyroid gland 132 9.20 (7.43–11.40) 8 5.77 (2.45–13.60) 33 3.57 (2.34–5.45) 3 1.77 (0.44–7.14) < .0001
Endocrine glands 114 3.53 (2.77–4.51) 11 1.41 (0.65–3.09) 63 1.55 (1.12–2.16) 28 2.00 (1.22–3.27) 0.0003
Non–Hodgkin lymphoma 82 1.76 (1.37–2.26) 39 1.84 (1.28–2.64) 174 1.61 (1.35–1.91) 112 1.57 (1.27–1.95) 0.83
Hodgkin lymphoma 57 7.26 (5.66–9.31) 2 4   0
Myeloma 4 1.21 (0.47–3.10) 6 2.13 (0.99–4.59) 31 2.23 (1.59–3.14) 42 2.48 (1.85–3.33) 0.47
Leukemia 92 2.09 (1.62–2.69) 32 2.21 (1.44–3.39) 145 1.80 (1.47–2.20) 133 2.25 (1.82–2.79) 0.48
Table 2.  Familial risk for cancers diagnosed at early and late ages. 1FDR = First-degree relative. 2P-value 
based on likelihood ratio test. 3N = Number of concordant cases. 4RR = Relative risk. 5CI = Confidence 
interval.
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for prostate cancer (5.25) and melanoma (4.47), when two siblings were affected, was about twice as high 
as the risk when one sibling was affected but the difference was only significant for prostate cancer. In 
the case of three affected siblings, the case numbers did not allow for reliable risk estimates, except for 
prostate cancer featuring an exceedingly high RR of 6.78.
Proportion of familial cancers among all cancers. The highest proportions of familial patients 
diagnosed at the age of 60 years or older were found for cancers of the prostate (21.9%), breast (14.4%), 
colorectum (13.8%), and lung (10.3%) as presented in Table 4. Apart from these types, almost all remain-
ing cancers showed percentages less than 5%. An overwhelming proportion (> 90%) of familial cancers 
were in families of two patients, with the exception of prostate cancer (87%). Families with three or more 
concordant cases accounted for more than 1% of all cancer only for prostate (2.9%) and breast cancer 
(1.1%).
Discussion
Our study showed that the existence of affected family members is an important risk factor for all cancer 
types. For common cancers familial risk even increased with the number of affected family members. 
Until now, over 100 cancer predisposing variants have been identified and in addition over 300 low-risk 
loci have been mapped15. However, only a small proportion of familial cancer can be explained by the 
established genetic predisposition, and the proposed risk estimates vary extensively16. For example, in 
colorectal cancer some studies have assumed that mismatch repair gene defects (hereditary non-polyposis 
colon cancer) account for most of familial aggregation17, but the recent exome sequencing data put the 
figure at 11% of familial cancer and early onset cases18. In clinical genetic counseling mutation testing 
is offered only for a few high-risk cancer predisposing genes. In Europe, the UK, Netherlands, and the 
Nordic countries offer genetic counseling services to some degree on cancers for which predisposing 
genes are not known but in the main continental Europe such counseling is rare. In Germany, guidelines 
for testing genetic predispositions emphasize on breast-ovarian and colorectal cancers19.
Family history
Cancer site
Colorectum Lung Breast Prostate
Urinary
bladder Melanoma Nervous system
Case 
numbers1, 
Relative risk, 
95%CI
Both parents affected
63 25 11 0 6 8 3
1.98 (1.46–2.69) 3.02 (1.86–4.92) 9.49 (4.58–19.67) 3.50 (0.92–13.28) 6.00 (2.54–14.15) 3.64 (0.82–16.17)
1 parent and 1 
sibling affected
186 42 485 930 12 50 24
3.67 (3.07–4.39) 2.48 (1.70–3.61) 2.88 (2.58–3.21) 4.59 (4.23–4.98) 2.86 (1.11–7.35) 8.20 (5.81–11.56) 9.47 (5.59–16.05)
2 siblings affected
33 27 199 368 3 15 0
2.57 (1.68–3.91) 3.39 (2.12–5.42) 2.50 (2.11–2.97) 5.25 (4.62–5.98) 2.74 (0.42–18.03) 4.47 (2.39–8.37)
3 siblings affected
4 4 4 44 0 0 0
6.59 (1.97–22.08) 20.84 (6.17–70.38) 1.02 (0.30–3.41) 6.78 (4.68–9.83)
P-values for 
differences 
among RRs2
Both parents vs. 1 
parent 0.36 0.0528 <.0001 0.31 0.0398 0.26
1 Parent and 1 
sibling vs. 1 parent <.0001 0.14 <.0001 <.0001 0.32 <.0001 <.0001
1 Parent and 1 
sibling vs. 1 sibling <.0001 0.95 <.0001 <.0001 0.41 <.0001 <.0001
2 siblings vs. 1 
sibling 0.25 0.22 0.0006 <.0001 0.71 0.13
3 siblings vs. 1 
sibling 0.0528 0.0007 0.34 <.0001
3 siblings vs. 2 
sibling 0.15 0.0063 0.15 0.20
1 Parent and 1 
sibling vs. 2 siblings 0.12 0.31 0.18 0.08 0.97 0.10
1 Parent and 1 
sibling vs. both 
parents
0.0006 0.53 0.0015 0.81 0.51 0.24
2 siblings vs. both 
parents 0.33 0.74 0.0005 0.83 0.59
Table 3.  Familial cancer risks for people with multiple affected relatives. 1Number of concordant cases 
2P-values from Wald chi-square statistics testing for pairwise differences among RRs for different family 
histories.
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Familial risk was assessed based on the FCD which is the world’s largest database for familial studies 
allowing for unbiased risk estimates in terms of selection and recall bias as the whole Swedish popula-
tion was covered with registered data on family relationships and medically verified data was available20. 
We showed that the cancer risks conferred by affected parents or siblings were about 2-fold compared 
to the risk for individuals with unaffected relatives. If a parent was affected, risks for offspring were 
highest, some 5-fold for cancers of the thyroid gland and small intestine. If a brother or sister was 
affected with small intestinal cancer or Hodgkin lymphoma the risk was increased 10-fold. Our previous 
study has shown a low correlation of familial risks in common cancers between spouses, suggesting that 
shared environment in adulthood is not an important risk factor for familial risk, with the exception of 
tobacco-related cancers such as lung cancer6. In this study, slightly higher risks for concordant cancers 
among siblings than for offspring of affected parents may indicate recessive genetic effects or deleterious 
influence of shared environmental risk factors during childhood and adolescence21. For some cancers 
such as stomach, lung and prostate cancers, and Hodgkin lymphoma these differences were highly sig-
nificant. Stomach cancer with sharp decline in incidence would show much higher rates in the parental 
than in the offspring generation22. For smoking, childhood environmental exposure is likely to facilitate 
persistent addiction23. For prostate cancer, in addition to the possible recessive effects, diagnosis of cancer 
in a brother may alert other brothers to seek medical contacts while diagnosis in a father may be of less 
concern24. For Hodgkin lymphoma, shared childhood socioeconomic environment has been offered as 
an explanation25.
We observed that familial RRs depend on age for most but not all cancers. This effect was already 
detected for some common cancers in a study based on a previous version of the FCD26. Now, we had 
a sufficiently large sample size to investigate even rarer cancers and most of them showed significantly 
different risks, as tested between the age groups, depending on the individual age and the family mem-
ber’s diagnostic age. For almost all cancers the individual cancer risk was highest below 60 years of age 
Cancer site
Number of cases (%) with 
a negative family history
Number of cases (%) with concordant 
cancers among first-degree relatives
2 affected FDR1
3 or more affect-
ed FDRs
Upper aerodigestive tract 2733 (97.1) 81 (2.9) 2 (0.1)
Esophagus 1251 (98.2) 23 (1.8) 0 (0)
Stomach 1958 (93.3) 133 (6.3) 7 (0.3)
Small intestine 611 (97.6) 14 (2.2) 1 (0.2)
Colorectum 12934 (86.2) 1940 (12.9) 126 (0.8)
Liver 2280 (96.3) 87 (3.7) 1 (0.0)
Pancreas 2823 (95.9) 116(3.9) 4 (0.1)
Lung 10215 (89.8) 1124 (9.9) 42 (0.4)
Breast 16469 (85.6) 2573 (13.4) 204 (1.1)
Cervix 623 (98.9) 7 (1.1) 0 (0)
Endometrium 4458 (96.1) 179 (3.9) 4 (0.1)
Ovary 2336 (96.6) 80 (3.3) 2 (0.1)
Prostate 29273 (78.1) 7148 (19.1) 1071 (2.9)
Testis 108 (99.1) 1 (0.9) 0 (0)
Kidney 3099 (96.6) 108 (3.4) 2 (0.1)
Urinary bladder 5711 (93.7) 378 (6.2) 9 (0.2)
Melanoma 5251 (94.5) 288 (5.2) 15 (0.3)
Skin, squamous cell 4564 (93.5) 307 (6.3) 12 (0.3)
Nervous system 3364 (96.6) 117 (3.4) 3 (0.1)
Thyroid gland 504 (97.9) 11 (2.1) 0 (0)
Endocrine glands 1764 (97.8) 37 (2.1) 2 (0.1)
Non-Hodgkin lymphoma 4072(96.4) 148 (3.5) 3 (0.1)
Hodgkin lymphoma 222 (99.1) 2 (0.9) 0 (0)
Myeloma 1690 (97.2) 48 (2.8) 0 (0)
Leukemia 3366 (95.3) 162 (4.6) 3 (0.1)
Table 4.  Number and percentage of cases with and without a concordant cancer in the family among 
individuals at age ≥ 60 years. 1FDR = First-degree relative.
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if the affected FDR was also diagnosed at that age. The risk declined considerably for elderly individuals 
if relatives were also diagnosed at late ages which was most obvious for colorectal and prostate cancers. 
For the latter, the corresponding RRs were reduced from 7.21 to 2.13 from early to late diagnostic age. 
Interestingly, this seemingly trend appeared to be reversed for myeloma, yet with small case numbers.
A high familial risk at an early age, shown above for most cancers, is in accord with the current 
understanding of cancer syndromes which disproportionately afflict young individuals27. However, the 
seemingly opposite information that significant familial risks and most familial cases in many cancers are 
in fact found in individuals older than 59 years (when family members were also diagnosed at high age) 
has implications with regard to clinical counseling: counselor should not overlook cancers diagnosed at 
an advanced age. A contributing reason for decreasing familial risks in the elderly population is the high 
background incidence28.
Familial relative risks were further increased if multiple FDRs were affected. For melanoma, risk 
shared by parents was almost identical to sibling risks, but it was more than doubled if both parents or a 
parent and a sibling were affected. The aggregation of affected family members in these few families may 
be due to genetic predisposition through the high-risk susceptibility gene CDKN2 or, to lesser extent, 
by shared modifiable risk factors such as UV radiation, as melanoma is known to be a heterogeneous 
disease with differing etiologies29. The risk for nervous system tumors was more than 5-fold higher if a 
parent and a sibling were affected compared to the risk conferred by affected parents or siblings only. This 
remarkable increase was already observed elsewhere30. Since ionizing radiation is the only thus far estab-
lished environmental risk factor for nervous system cancer31, the majority of familial cases where two 
family members were affected is probably caused by low-penetrance genes while rare cancer syndromes 
such as Li-Fraumeni, neurofibromatosis 1 and 2, von Hippel–Lindau, tuberous sclerosis, Turcot, and 
Gorlin would account for multiplex families32,33. The proportional increase in prostate cancer risk and 
number of affected relatives support the hypothesis of rare autosomal dominant susceptibility genes34. 
Furthermore, high-risk cancer predisposing genes such as BRCA1/BRCA2 associated with familial breast 
cancer or mismatch repair genes involved in Lynch syndrome (hereditary non-polyposis colon cancer) 
may account for significantly increased risk of breast and colorectal cancers in the cluster of affected 
parents and siblings. Interestingly, the corresponding risks for two affected siblings were also elevated, 
but only modestly and the difference was significant only for breast cancer. Successful screening of family 
members of mutation carriers may have prevented some breast and colorectal cancers in recent dec-
ades1,2. In families where both parents and offspring suffer from breast cancer, mutations in the BRCA1 
gene, which were estimated to account for 60% to 76% of male breast cancers in high-risk families, are 
most likely to be causative35.
Most familial cancers were diagnosed at the age of 60 years or older. Among them, the number of 
families where 3 or more family members were diagnosed with a concordant cancer was negligible, with 
the exception of the most common cancers of the prostate and breast. The low proportion of families with 
3 or more affect individuals is likely to define the genetic architecture of familial cancer; high-penetrance 
predisposition is rare compared to low-penetrance risk disposition signaled by two-case families.
In conclusion, our results show that familial risk is a shared feature of all cancers and for many 
cancers multiple affected family members signal a high or very high risk that would necessarily require 
medical action. Some of such families are likely carriers of known high-risk cancer predisposition genes. 
However, the major proportion of familial cluster is probably caused by genes that remain to be discov-
ered. Nevertheless, medical or behavioral intervention may be indicated, including screening recom-
mendations or avoidance of carcinogenic exposures. The readily available information of family history 
deserves more attention in the first oncology contacts and established referral mechanisms for clinical 
counseling to evaluate screening and prevention strategies individually tailored to patients and their 
family members.
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